Shares of Spyglass Pharma, Inc. (NASDAQ:SGP – Get Free Report) gapped down before the market opened on Thursday. The stock had previously closed at $31.43, but opened at $29.73. Spyglass Pharma shares last traded at $28.47, with a volume of 5,982 shares.
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on the company. Stifel Nicolaus raised their price target on Spyglass Pharma from $42.00 to $44.00 and gave the company a “buy” rating in a research report on Friday, November 13th. Raymond James Financial initiated coverage on shares of Spyglass Pharma in a research report on Friday, August 14th. They issued an “outperform” rating and a $39.00 price objective on the stock. HC Wainwright increased their price objective on shares of Spyglass Pharma from $37.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, November 12th. UBS Group restated a “buy” rating on shares of Spyglass Pharma in a report on Monday, October 5th. Finally, Wall Street Zen upgraded shares of Spyglass Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.83.
View Our Latest Report on Spyglass Pharma
Spyglass Pharma Stock Down 1.1%
The business has a 50 day moving average of $29.07 and a 200-day moving average of $24.98.
Spyglass Pharma (NASDAQ:SGP – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.07). As a group, equities analysts forecast that Spyglass Pharma, Inc. will post -2.77 earnings per share for the current year.
Insider Buying and Selling
In other news, Director Ra Capital Management, L.P. bought 1,000 shares of the business’s stock in a transaction that occurred on Monday, November 16th. The stock was purchased at an average price of $32.43 per share, with a total value of $32,430.00. Following the purchase, the director owned 5,967,439 shares of the company’s stock, valued at $193,524,046.77. This trade represents a 0.02% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.
Institutional Investors Weigh In On Spyglass Pharma
Hedge funds have recently modified their holdings of the company. First Light Asset Management LLC purchased a new stake in shares of Spyglass Pharma during the first quarter worth about $9,716,000. Affinity Asset Advisors LLC purchased a new position in shares of Spyglass Pharma during the first quarter valued at approximately $6,478,000. Bank of America Corp DE purchased a new position in shares of Spyglass Pharma during the first quarter valued at approximately $726,000. Bank of New York Mellon Corp acquired a new stake in Spyglass Pharma during the second quarter worth approximately $533,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Spyglass Pharma during the first quarter worth approximately $308,000.
Spyglass Pharma Company Profile
SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops. The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.
See Also
- Five stocks we like better than Spyglass Pharma
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
